MarketCapTrends
PLX

Protalix Biotherapeutics Inc. (PLX)

NYSE · Healthcare

Protalix Biotherapeutics Inc. annual/quarterly shareholder equity history from 2010 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • Protalix Biotherapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 48.2M, a 11.62% increase year-over-year.
  • Protalix Biotherapeutics Inc. shareholder equity for 2025 were 48.2M, a 11.62% increase from 2024.
  • Protalix Biotherapeutics Inc. shareholder equity for 2024 were 43.2M, a 28.72% increase from 2023.
  • Protalix Biotherapeutics Inc. shareholder equity for 2023 were 33.6M, a 415.50% decrease from 2022.
  • Protalix Biotherapeutics Inc. shareholder equity for 2022 were -10.6M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Protalix Biotherapeutics Inc. Annual Shareholder Equity (Millions of US $)
2025$48
2024$43
2023$34
2022$-11
2021$-6
2020$-27
2019$-70
2018$-53
2017$-29
2016$-10
2015$11
2014$-56
2013$-27
2012$-3
2011$-26
Protalix Biotherapeutics Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$48
2024-12-31$43
2023-12-31$34
2022-12-31$-11
2021-12-31$-6
2020-12-31$-27
2019-12-31$-70
2018-12-31$-53
2017-12-31$-29
2016-12-31$-10
2015-12-31$11
2014-12-31$-56
2013-12-31$-27
2012-12-31$-3
2011-12-31$-26
2010-12-31$-11

Protalix Biotherapeutics Inc. Shareholder Equity — FAQ

Protalix Biotherapeutics Inc. (PLX) shareholder equity over the last 17 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see PLX's shareholder equity history?

The chart and table above show Protalix Biotherapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.